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Nitric oxide (NO) plays a relevant role during cell death regulation in tumor cells. The overexpression of
nitric oxide synthase type III (NOS-3) induces oxidative and nitrosative stress, p53 and cell death receptor
expression and apoptosis in hepatoblastoma cells. S-nitrosylation of cell death receptor modulates
apoptosis. Sorafenib is the unique recommended molecular-targeted drug for the treatment of patients
with advanced hepatocellular carcinoma. The present study was addressed to elucidate the potential role
of NO during Sorafenib-induced cell death in HepG2 cells. We determined the intra- and extracellular NO
concentration, cell death receptor expression and their S-nitrosylation modiﬁcations, and apoptotic
signaling in Sorafenib-treated HepG2 cells. The effect of NO donors on above parameters has also been
determined. Sorafenib induced apoptosis in HepG2 cells. However, low concentration of the drug (10 nM)
increased cell death receptor expression, as well as caspase-8 and -9 activation, but without activation of
downstream apoptotic markers. In contrast, Sorafenib (10 mM) reduced upstream apoptotic parameters
but increased caspase-3 activation and DNA fragmentation in HepG2 cells. The shift of cell death sig-
naling pathway was associated with a reduction of S-nitrosylation of cell death receptors in Sorafenib-
treated cells. The administration of NO donors increased S-nitrosylation of cell death receptors and
overall induction of cell death markers in control and Sorafenib-treated cells. In conclusion, Sorafenib
induced alteration of cell death receptor S-nitrosylation status which may have a relevant repercussion
on cell death signaling in hepatoblastoma cells.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Nitric oxide (NO) is a lipophilic, highly diffusible, and short-
lived physiological messenger [1]. NO is synthesized by three
different gene-encoded NO synthases (NOS) in mammals: neuro-
nal NOS (nNOS or NOS-1), inducible NOS (iNOS or NOS-2) and
endothelial NOS (eNOS or NOS-3). The expression of NOS-2 is in-
duced by inﬂammatory stimuli, while NOS-1 and NOS-3 are con-
stitutively expressed [2]. NO regulates a variety of important
physiological responses, including vasodilation, respiration, cell
migration, immune response and apoptosis. Different clinical trials
have demonstrated that the infusion of NO donors increases the
effectiveness of chemotherapy and radiotherapy in patients with
cancer [3,4]. NO appears to induce genotoxic lesions, and promotes
angiogenesis, tumor cell growth, and invasion [5]. However, NO is
able to exert antitumoral properties, as well as increase suscept-
ibility to chemotherapy in different experimental in vivo and in
vitro models [6].
The key hallmarks of cancer cells are unlimited replicative
potential, insensitivity to growth-inhibitory signals, evasion of
apoptosis, cellular stress, and sustained angiogenesis, invasiveness
and metastatic potential [7]. The extension of several physio-
pathological mechanisms involved in cell proliferation, and
homeostasis is limited by the co-activation of the cell death pro-
cess [8]. The expression of proteins that promote cell proliferation
and tumor progression requires the expression of antiapoptotic
proteins or the inactivation of essential proapoptotic proteins in
order to progress [9]. This assumption is conﬁrmed by the ﬁnding
that deregulated proliferation alone is not sufﬁcient for tumor
formation. The acquisition of resistance of tumor cells to apoptosis
is an essential feature of cancer development. Cell death receptors,
such as the tumor necrosis factor receptor type I (TNF-R1, p55,
DR1), Fas/APO-1 (CD95, DR2), and tumor necrosis factor-related
apoptosis-inducing ligand type I (TRAIL-R1, DR4) and type II
(TRAIL-R2, DR5), are members of the tumor necrosis factor re-
ceptor (TNF-R) family. All members within the family are char-
acterized by the presence of a cysteine-rich extracellular domain,
which deﬁnes their ligand speciﬁcity [10,11], and a cytoplasmic
death domain of around 80 amino acids, which plays a central role
in the activation of the caspase-dependent pathway and induction
of apoptosis [12,13].
We [14] and others [15] have shown that NO sensitizes tumor
cells by increasing cell death receptor expression on cancer cells.
The post-translation modiﬁcations of the cell death receptors
might promote or prevent its redistribution into lipid rafts and
consequently, their susceptibility to cell death. In particular, pro-
apoptotic stimuli, such as CD95L, induce an epidermal growth
factor receptor (EGFR)-catalyzed tyrosine phosphorylation of
CD95-death receptor in hepatocytes, as a prerequisite for CD95-
translocation to the plasma membrane, formation of the DISC and
execution of apoptotic cell death [16]. In contrast, CD95 tyrosine
nitration by peroxinitrite prevents its phosphorylation and cell
death in Huh 7 cells [17]. NO donor or NOS-2 overexpression in-
duces S-nitrosylation of Cys199 and Cys304, located in the cyto-
plasmic domain of CD95, increasing its migration to lipid raft and
apoptosis in colon and breast cancer cells [18].
The administration of antitumoral agents, such as doxorubicin,
cisplatin, adriamycin and bleomycin increases the expression of
cell death receptors and/or their ligands, as well as other compo-
nents of the cell death pathways such as Fas-associated death
domain (FADD), pro-caspase-8, pro-caspase-3, the long isoform of
pro-caspase-2 and Bax in different carcinoma cell lines [19–23].
Sorafenib, a multi-kinase inhibitor which inhibits proliferation and
angiogenesis, is the recommended treatment for patients with
locally advanced/metastatic hepatocarcinoma [24,25]. The in-
creased susceptibility to cell death by Sorafenib is associated withdown-regulation of cell survival pathways in hepatoma cells
[26,27]. However, discrepancies exist regarding the regulation of
extrinsic cell death pathways by Sorafenib in different tumor cell
lines [28,29]. In addition, Sorafenib has been shown to dose-de-
pendently induce oxidative stress, such as superoxide anion
(O2  ), hydrogen peroxide (H2O2) and NO, in HepG2 cells [30]. The
aim of the present study was to determine the capacity of Sor-
afenib to regulate the expression of cell death receptor and/or its
S-nitrosylations, as well as extrinsic apoptotic signaling in hepa-
toblastoma cells. Data showed that the drug reduces S-nitrosyla-
tion of cell death receptors which was related to a shift from
moderate extrinsic cell death pathway to drastic increase of
downstream apoptotic markers in HepG2 cells.2. Material and methods
2.1. Materials
All reagents were from Sigma-Aldrich Chemical Co. (St Louis,
Missouri, USA) unless otherwise stated. 4-Amino-5-methylamino-
2′,7′-diﬂuoroﬂuorescein diacetate (DAF-FM) was obtained from
Molecular Probes (Cat. D-23842). S-nitroso-L-cysteine (CSNO) was
prepared according to the procedure described elsewhere [31] by
incubation of L-cysteine with acidiﬁed sodium nitrite and quanti-
ﬁcation by absorbance at 334 nm using a molar absorption coef-
ﬁcient of 0.74 mM1 cm1. Sorafenib Tosylate was purchased from
Carbosynth (Carbosynth Ltd., Berkshire, United Kingdom).The
study protocol has been approved by the Ethical Committee of the
Institution.
2.2. Cell lines and culture conditions
HepG2 cell line was obtained from the ATCC-LGC (Barcelona,
Spain). Cells were negative for mycoplasma contamination. Cells
were routinely maintained in EMEM (Eagle´s Minimum Essential
Medium) (Sigma-Aldrich Chemical Co) pH 7.4 supplemented with
10% fetal bovine serum (F7524, Sigma-Aldrich, Lot No: 022M3395,
endotoxin o0.2 EU/ml), 2.2 g/l HCO3Na, 1 mM sodium pyruvate,
100 U/ml penicillin, 100 mg/ml streptomycin, 0.25 mg/ml ampho-
tericin and the corresponding selection antibiotic in 5% CO2 in air
at 37 °C.
Cells were maintained for 24 h before administration of Sor-
afenib (0, 10 nM and 10 mM). 1,1-Diethyl-2-hydroxy-2-nitroso-hy-
drazine sodium (NONOate) (5 mM) or CSNO (5 mM) was adminis-
tered 30 min before Sorafenib, and maintained for 48 h. The
parameters were assessed at 12, 24 and 48 h after Sorafenib ad-
ministration. Culture medium was replaced every 24 h.
2.3. Measurement of cell death
Caspase-8, Caspase-9 and Caspase-3-associated activity were
determined using Caspase-Glos Assay Systems (G8201, G8211 and
G8091, Promega, Madison, Wisconsin, USA). Cells were treated
with Caspase-Glos Reagent in an “add-mix-measure” format re-
sulting in cell lysis, caspase-8-dependent cleavage of the substrate
and generation of a “glow-type” luminescent signal. The signal
generated is proportional to the amount of caspase activity. The
values are extrapolated into a calibration curve included in the
assay.
HepG2-ﬁxed cells cultured in glass-Petri dish were used for
measuring apoptosis by TUNEL assay (Promega, G3250). The assay
measures the fragmented DNA of apoptotic cells by catalytically
incorporating ﬂuorescein-12-dUTP at 3′-OH DNA ends using the
enzyme Terminal Deoxynucleotidyl Transferase (TdT), which
forms a polymeric tail using the principle of the TUNEL assay. The
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Fig. 1. Regulation of TNF-R1 (A), CD95 (B) and TRAIL-R1 (C) expression by Sor-
afenib in HepG2 cells. The expression of cell death receptors has been assessed by
Western-blot analysis at 24 and 48 h after Sorafenib (0, 10 nM and 10 mM) ad-
ministration. GAPDH was used as internal protein loading. The statistical analysis of
densitometric values of the spots is shown below the blot. Data are expressed as
mean7SEM. The groups with different letters (a, b, c, d or e) were signiﬁcantly
different (pr0.05). The images are representative of six independent experiments.
A. Rodríguez-Hernández et al. / Redox Biology 6 (2015) 174–182176ﬂuorescein-12-dUTP-labeled DNA was visualized using an Olym-
pus BX61 microscope. Fluorescence quantiﬁcation was performed
using Leica Application Suite Advanced Fluorescence software and
ImageJ software.
2.4. Expression of TNF-R1, CD95 and TRAIL-R1
Cells were washed twice with PBS (with Ca2þ) and treated with
lysis buffer (50 mM HEPES pH. 7.5, 150 mM NaCl, 5 mM EDTA, 1%
NP-40) including 1 mM PMSF, 1 mM NaF, 1 mM Na3VO4 and a
commercial protease inhibitor cocktail containing AEBSF-HCl
(Serine protease), Aprotinin (Serine protease), Bestatin (Amino-
peptidase B and Leucine Aminopeptidase), E-64 (Cysteine pro-
tease), Leupeptine (Cysteine protease and trypsin-like serine pro-
teases), Pepstatin A (Aspartic proteases) (P8340, Sigma-Aldrich
Chemical Co.). Culture medium was collected and centrifuged for
5 min 4 °C at 400 g, and detached cells transferred to cell lysate,
and maintained for 20 min on ice with vortex each 5 min. After
centrifugation at 15,520 g for 5 min at 4 °C, the supernatant was
stored at 20 °C for the measurement of NO-end products. The
expression of TNF-R1, CD95 and TRAIL-R1 protein expression were
determined by SDS-PAGE coupled to Western-blot analysis. Pro-
teins (50–100 μg) were separated by 10–12% SDS-PAGE and
transferred to PVDF membranes. The membranes were incubated
with the corresponding commercial primary antibodies against
TNF-R1 (1/250) (sc-7895, Santa Cruz Biotechnology Inc.), CD95 (1/
250) (sc-715, Santa Cruz Biotechnology Inc.; Delaware, California,
USA), and TRAIL-R1 (1/250) (sc-6823, Santa Cruz Biotechnology
Inc.). The corresponding anti-rabbit (1/10000) (sc-2301, Santa Cruz
Biotechnology, Inc.), anti-mouse (1/10000) (sc-2031, Santa Cruz
Biotechnology Inc.,) or anti-goat (1/10000) (sc-, Santa Cruz Bio-
technology, Inc.) secondary antibodies were coupled to horse-
radish peroxidase revealing protein content by Pierce ECLWestern
Blotting Substrate (Thermo Scientiﬁc, Waltham, Massachusetts,
USA). G3PDH (0.05 μg/ml) (G8795, Sigma) were used as cell pro-
tein loading control in cell membrane embedded proteins.
2.5. Measurement of NO
The production of NO was measured by quantiﬁcation of its
related end products, nitrite/nitrate in culture medium obtained as
described above. In the assay, nitrate was converted to nitrite by
nitrate reductase (EC 1.6.6.2) and total nitrite was measured using
the Griess reaction [32]. Brieﬂy, the samples were incubated with
nitrate reductase (0.2 U/ml), FAD (5 mM) and NADPH (50 mM) for
20 min at 37 °C. The reaction was stopped by the addition of so-
dium pyruvate (10 mM) and lactate dehydrogenase (24 mg/ml) for
5 min at 37 °C, and precipitated with 1.4% ZnSO4. Total nitrite re-
acted with Griess reagent (1% sulfanilamide, 2.5% PO4H3, 0.1%
n-naphthyl-ethylene-diamine) for 10 min at 37 °C, and was read at
540 nm using a Inﬁnite 200 PRO Microplate Reader (TECAN).
The in situ production of NO was monitored using a ﬂuorescent
probe, such as DAF-FM diacetate (D-23842, Molecular Probes
Europe BV, Leiden, The Netherlands), hydrolyzed by intracellular
esterases to form DAF-FM in cytoplasm, and oxidized by NO to
yield the highly ﬂuorescent Triazole form (DAF-FM-T). Stock so-
lution of DAF-FM diacetate was maintained in DMSO and stored at
20 °C until use. Cells were incubated with DAF-FM diacetate
(2.5 μM) for 30 min in culture medium. Cells were washed with
PBS, in order to avoid any interference with the measurement of
cell ﬂuorescence. The production of NO was in situ assessed as the
enhancement on the ﬂuorescence at Ex 495 nm/Em 515 nm
measured using a Inﬁnite 200 PRO Microplate Reader (TECAN).
The corresponding controls were carried out in cells incubated in
the presence/absence of solvent, dye and cells.2.6. Detection of S-nitrosylation in cell death receptors by the biotin
switch assay
The procedure was performed as previously described [33]
with recently described modiﬁcations [34]. Cells were treated with
lysis solution (50 mM Tris–HCl pH 7.4, 300 mM NaCl, 5 mM EDTA,
0.1 mM neocuproine, 1% Triton X-100, 5 mg/mL aprotinin and
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Fig. 2. Regulation of caspase-8 (A), caspase-9 (B), caspase-3 (C) and DNA fragmentation (D) by Sorafenib in HepG2 cells. The activity of caspases was detected by commercial
chemiluminescence-based assay. DNA fragmentation was determined by TUNEL assay. The variables were evaluated at 24 and 48 h after Sorafenib (0, 10 nM and 10 mM)
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The images obtained from TUNEL assays are representative of three independent experiments.
A. Rodríguez-Hernández et al. / Redox Biology 6 (2015) 174–182 17710 mg/mL leupeptin), and after centrifugation at 10,000 g the su-
pernatants (0.5 mg/mL) were incubated with 4 volumes of blocking
buffer (225 mM HEPES, pH 7.7, 0.9 mM EDTA, 90 mM neocuproine,
2.5% SDS and 20 mM methyl methane thiosulfonate or MMTS) for
20 min at 50 °C, and precipitated with 3–4 volumes of cold acet-
one. The dried pellet was resuspended in 500 mL HENS (HEN and
1% SDS) with 100 mM sodium ascorbate and 167 mL 4 mM Biotin-
HPDP for 1 h, precipitated with cold acetone, and dried pellet re-
suspended in 200 mL HENS buffer and 800 mL of neutralization
buffer (20 mM HEPES pH 7.7, 100 mM NaCl, 1 mM EDTA, 0.5%
Triton X-100). Samples were treated with 45 mL Neutravidin Plus
UltralinK resin (Pierce) for 1 h in agitation, washed (20 mM HEPES
pH 7.7, 600 mM NaCl, 1 mM EDTA and 0.5% Triton X-100), and
incubated in 20 mM HEPES pH 7.7, 100 mM NaCl, 1 mM EDTA, and
100 mM 2-mercaptoethanol for 20 min at 37 °C. After centrifuga-
tion, supernatants were loaded into 10% SDS-PAGE electrophoresisin reducing conditions. The expression of cell death receptors was
detected by Western Blot analysis as described above.2.7. Statistical analysis
Results are expressed as mean7SE of three (TUNEL and biotin
switch assays), six (Western-blot images) and seven (caspase ac-
tivities and NO-related measurements) independent experiments.
Normal distribution was assessed by Shapiro–Wilk test. Homo-
geneity of variances was determined by Levene test. Data were
compared using the analysis of variance with the Least Signiﬁcant
Difference’s test as post-hoc multiple comparison analysis. The
statistical differences were set at pr0.05. The groups in the bar
graphs showing different letters (a–e) were statistically different.
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Fig. 3. Regulation of NO generation and S-nitrosylation of TNF-R1 (C), CD95 (D) and TRAIL-R1 (E) by Sorafenib in HepG2 cells. NO intracellular (A) and extracellular
(B) concentrations were determined using DAF-FM and NO-end products, respectively. S-nitrosylation was assessed by the biotin switch assay which was coupled to
Western-blot analysis at 24 and 48 h after Sorafenib (0, 10 nM and 10 mM) administration. The statistical analysis of densitometric values of the spots is shown below the blot.
Data are expressed as mean7SEM of seven independent experiments. The groups with different letters (a, b, c, d or e) were signiﬁcantly different (pr0.05). The images are
representative of three independent experiments (biotin switch) and six independent experiments (NO-related measurements).
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3.1. Induction of apoptosis by Sorafenib
Sorafenib increases cell death in hepatoma cells [26]. However,
discrepancies exist between the involvement of extrinsic and in-
trinsic cell death pathway during Sorafenib-induced cell death
[28,35]. Sorafenib dose-dependently regulated apoptotic cell sig-
naling in hepatoblastoma cells. The expression of cell death re-
ceptors (TNF-R1, CD95 and TRAIL-R1) (Fig. 1), as well as caspase-8
(Fig. 2A) and -9 (Fig. 2B) activation was induced at 24 h after ad-
ministration of Sorafenib at low concentration (10 nM). However,
higher concentration of Sorafenib (10 mM) reduced the above
markers, and promoted the activation of downstream apoptotic
markers such as caspase-3 (Fig. 2C) and TUNEL-staining (Fig. 2D)
in HepG2 cells. Although the expression of cell death receptors
(CD95 and TRAIL-R1) was still increased at low concentration of
Sorafenib (10 nM), a signiﬁcant rise of caspase-3 activity was ob-
served that correlated with a reduction of caspase-8 and -9 at
48 h. High doses of Sorafenib (10 mM) increased both extrinsic and
intrinsic pathways at 48 h in HepG2 cells.
3.2. Regulation of NO-generation and S-nitrosylation of cell death
receptors by Sorafenib
Sorafenib increased NO intracellular concentration measured
by DAF-FM (Fig. 3A, 24 h) and NO-end products in culture medium
(Fig. 3B, 24 h). The rise of NO-end product concentration was only
observed at low Sorafenib concentration (10 nM). The medium
was replaced every 24 h, so the measurement of NO-end product
concentration in culture medium corresponds to its accumulation
between 0–24 h and 24–48 h. This fact may explain the reduction
of NO-end product concentration in culture medium from cells
treated with high dose of Sorafenib (10 mM) at 48 h in which NO
release appeared to be lower compared to that observed at 0–
24 hours. Interestingly, this effect of the drug was related to adrastic dose-dependent reduction of S-nitrosylation in TNF-R1
(Fig. 3C) and CD95 (Fig. 3D). S-nitrosylation of TRAIL-R1 was not
detected in the absence of NO donor (data not shown).
3.3. Role of NO-donor on cell death in control and Sorafenib-treated
hepatoblastoma cells
The administration of NO donors increased the expression of
cell death receptor in control cells (Fig. 4A), as well as S-ni-
trosylation of TNF-R1 (Fig. 4C), CD95 (Fig. 4D) and TRAIL-R1 (4E) in
control cells. The estimation of S-nitrosylation/expression ratio
showed that CSNO increased S-nitrosylation of cell death receptor
stronger than NONOate in control cells (Fig. 4F). The administra-
tion of Sorafenib (10 mM) changed the effect of NO donors in
HepG2. In this sense, Sorafenib reduced the increase of cell death
receptor expression induced by NO donors to values close to
control levels (TNF-R1 and TRAIL-R1) (Fig. 4B), as well as the effect
of NO donors on S-nitrosylation of cell death receptors (Fig. 4C–E)
in HepG2 cells. Interestingly, the estimation of S-nitrosylation/
expression ratio showed that Sorafenib reduced S-nitrosylation of
CD95 and TRAIL-R1 in NO donor-treated cells (Fig. 4G). The ad-
ministration of NO donors increased caspase-8 (Fig. 5A), caspase-9
(Fig. 5B) and caspase-3 (Fig. 5C) in control and Sorafenib-treated
cells.4. Discusion
The biological activity of NO may be through cGMP-dependent
and cGMP-independent pathways which play a relevant role in
pathophysiological conditions [36]. NO induces cGMP-dependent
protein kinases, cyclic-nucleotide-gated ion channels and cGMP-
regulated phosphodiesterases [6]. However, during the last decade
cGMP-independent reactions gained considerable interest. A
variety of effects are achieved through its interactions with targets
via redox and additive chemistry, that may promote covalent
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Fig. 4. Effect of NO donors on the expression of cell death receptors in control (A) and Sorafenib (B)-treated HepG2 cells, as well as the S-nitrosylation of TNF-R1 (C), CD95
(D) and TRAIL-R1 (E) in cells. NONOate (5 mM) or CSNO (5 mM) was administered 30 min before Sorafenib (10 mM). S-nitrosylation was assessed by the biotin switch assay
which was coupled to Western-blot analysis at 24 h after Sorafenib administration. The estimation of S-nitrosylation/expression ratio of cell death receptor is shown in
control (F) and Sorafenib (G)-treated cells. The statistical analysis of densitometric values of the spots is shown below the blot. Data are expressed as mean7SEM. The groups
with different letters (a, b, c, d or e) were signiﬁcantly different (pr0.05). The images are representative of three independent experiments.
A. Rodríguez-Hernández et al. / Redox Biology 6 (2015) 174–182 179modiﬁcations of intracellular proteins as well as oxidation events
that do not require attachment of the NO group [37]. The most
prominent and recognized NO reaction with thiols groups of cy-
steine residues is called S-nitrosylation or S-nitrosation, which
leads to the formation of more stable nitrosothiols [38].
Several NO-dependent signal transduction pathways are re-
lated to protein S-nitrosylation, which in terms of cell death may
exert either pro-apoptotic activity as a consequence of the al-
teration of mitochondrial potential and free radical generation
[39], or anti-apoptotic such as GSNO- or thioredoxin-dependent
S-nitrosylation of caspases [40], PKCε which reduces cFLIP release
from DISC complex [41], and cFLIP avoiding its degradationthrough proteosomal degradation [42].
The key hallmarks of cancer cells are unlimited replicative
potential, insensitivity to growth-inhibitory signals, evasion of
apoptosis, cellular stress, and sustained angiogenesis, invasiveness
and metastatic potential [7]. The alteration of cell death signaling
is frequently observed in cancer [43–45]. The role of NO in tumor
progression depends on the activity and localization of NOS iso-
forms, concentration and duration of NO exposure, cellular sen-
sitivity, and hypoxia/re-oxygenation status [36]. The induction of
nitrosative stress increases CD95 expression and cell death in
pulmonary artery smooth muscle cells [46] and neurons [47]. We
have recently shown that p53 mediates the increase of cell death
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A. Rodríguez-Hernández et al. / Redox Biology 6 (2015) 174–182180receptor expression and cell death induced by the exogenous ad-
ministration of NO donor and/or NOS-3 overexpression in differ-
entiated hepatoma cells lines [14]. In addition, S-nitrosylation of
critical cysteine residues of CD95 modulates CD95 membrane
trafﬁcking and cell death stimulation in hepatoma cancer cells
[18]. The induction of caspase-8 activation was also related to
S-nitrosylation of TRAIL-R1 in melanoma (A375), renal carcinoma
(ACHN), and ovarian carcinoma (NIH-OVCAR-3) cells treated with
nitrosylcobalamin [48].
Sorafenib, a multi-kinase inhibitor which inhibits proliferation
and angiogenesis, is the recommended treatment for patients withlocally advanced/metastatic hepatocarcinoma [24,25]. Sorafenib
exerts antitumoral activity targeting tyrosine kinase proliferating
receptor, and on Raf-1 and B-Raf thus inhibiting RAF/MEK/ERK
signaling pathway [49]. Although, Sorafenib increases apoptosis
several discrepancies exist regarding the involvement of extrinsic
or intrinsic pathways by Sorafenib in different tumor cell lines
[28,29].
The present study demonstrated that low concentration of
Sorafenib (10 nM) was able to increase the expression of cell death
receptors (TNF-R1, CD95 and TRAIL-R1) that correlated to high
caspase-8 and -9 activities but without signiﬁcant increase of
downstream apoptotic signaling such as caspase-3 activity and
DNA fragmentation (Figs. 1 and 2). Interestingly, high Sorafenib
concentration (10 mM) reduced basal level of cell death receptor
expression and caspase-8 and -9 activation, but increased all those
related to downstream apoptotic signaling at 24 h after adminis-
tration. Caspase-8 and -9 activities relapse at 48 h in cells treated
with high Sorafenib concentration. The present study and other
[30] have shown an increased NO production induced by Sorafenib
in hepatoma cells. The administration of Sorafenib increased the
intracellular NO concentration (DAF-FM) and in culture medium
(NO-end products) that were related to reduction of S-nitrosyla-
tion of cell death receptors (TNF-R1 and CD95) (Fig. 3). This effect
was particularly evident in cells treated with high Sorafenib con-
centration (10 mM) at 24 h. In these conditions, the expression of
cell death receptors, as well as caspase-8 and -9 activities were
reduced compared to control level (Figs. 1 and 2). It were inter-
esting to observe that the recovery of TNF-R1 and TRAIL-R1 ex-
pression, as well as caspase-8 and -9 in cells treated with Sor-
afenib (10 mM) (Figs. 1 and 2) were related to a recovery of S-ni-
trosylation of TNF-R1 (Fig. 3) at 48 h. Our data suggest that Sor-
afenib might transitorily activate denitrosylating-like activity.
Thioredoxin-1 has been shown to actively denitrosylated cytosolic
caspase-3 and thereby maintains a low steady-state amount
of S-nitrosylation [50]. CSNO treatment also increased S-ni-
trosoglutathione reductase (GSNOR) activity that reduces SNO
content in human hepatocytes [51].
The administration of low concentrations of NO donor such as
CSNO and NONOate (5 mM) induced a permissive induction of cell
death (up to 48 h). This experimental approach allows us to
combine NO donor and Sorafenib treatments. NO donors drasti-
cally induced S-nitrosylation of cell death receptors and increased
caspase-8, caspase-9 and caspase-3 activities in control cells. The
estimation of S-nitrosylation/expression ratio showed that CSNO
was more effective than NONOate inducing S-nitrosylation of cell
death receptor (Fig. 4E). This could be due to the characteristic of
CSNO molecule, which is a permeable nitrosothiol whose effect in
the induction of S-nitrosylation is more efﬁcient than NONOate.
However, this difference was not accompanied with a reduction of
caspase-8 and -9 activation by NONOate compared to CSNO
treatment. Sorafenib (10 mM) reduced the expression of cell death
receptors and their S-nitrosylation of cell death receptors (TNF-R1
and CD95) compared to the level observed in control and NO
donor-treated HepG2 cells (Figs. 1, 3, 4B–E). Interestingly, Sor-
afenib (10 mM) reduced the estimated value of S-nitrosylation/ex-
pression ratio in NO donor-treated cells. S-nitrosylation of cell
death receptors seems to be relevant for their trafﬁcking to lipid
raft and induction of apoptosis in hepatocytes [18]. In con-
cordance, the reduction of cell death receptor S-nitrosylation by
Sorafenib was related to a reduction of caspase-8 and -9, but a
relevant increase of caspase-3 in HepG2 cells (24 h). The presence
of NO generation system in cell membrane may be relevant for cell
signaling. In this sense, the antitumoral properties of NOS-3 ob-
served by our group [14,52] may be reinforced by its localization in
lipid raft domains or caveolae fraction [53]. In this sense, the ex-
trinsic cell death signaling has been shown to be regulated by
A. Rodríguez-Hernández et al. / Redox Biology 6 (2015) 174–182 181caveolin-1, a speciﬁc protein of lipid raft compartment, in phy-
siopathological cellular conditions [54–56].
The present study suggests that the down-regulation of S-ni-
trosylation of cell death receptors by Sorafenib may be critical to
reinforce its downstream pro-apoptotic properties of the drug
overwhelming upstream survival pathways in hepatoma cells.
More studies will allow the identiﬁcation of potential deni-
trosylating activity induced by Sorafenib which may affect the
trafﬁcking or activity of cell death receptors into lipid raft in he-
patoblastoma cells.Acknowledgments
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